---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-018449"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:37:35.470378+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ionis Phase 3 Balance study of olezarsen meets primary endpoint; reduces acute pancreatitis in FCS

## Summary
- Olezarsen 80 mg reduced fasting triglycerides by 44% vs placebo at 6 months (p<0.001).
- Acute pancreatitis events: 1 event in 80 mg group vs 11 in placebo over 12 months.
- All-cause hospitalizations reduced by 84% (placebo-adjusted) from baseline to 12 months.
- No serious treatment-emergent AEs related to olezarsen; serious AEs 14% (80 mg) vs 39% placebo.
- Ionis to pursue regulatory approval for first potential FCS treatment in U.S.; data published in NEJM.

## SEC filing metadata
- accession: 0001140361-24-018449
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/0001140361-24-018449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/ef20026226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-018449
- JSON: https://secwatch.observer/filing/0001140361-24-018449.json
- Plain text: https://secwatch.observer/filing/0001140361-24-018449.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.